[
  {
    "ts": null,
    "headline": "Pfizer Q2 Earnings Beat Estimates, Oncology Drives Top-Line Growth",
    "summary": "PFE posts strong Q2 results with earnings up 30% and revenues up 10% year over year, fueled by rising oncology sales and cost cuts.",
    "url": "https://finnhub.io/api/news?id=75074261725446eeeba9679070714bcab3633909fe0f897531d2ff6f7ef91d58",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754408820,
      "headline": "Pfizer Q2 Earnings Beat Estimates, Oncology Drives Top-Line Growth",
      "id": 136215026,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "PFE posts strong Q2 results with earnings up 30% and revenues up 10% year over year, fueled by rising oncology sales and cost cuts.",
      "url": "https://finnhub.io/api/news?id=75074261725446eeeba9679070714bcab3633909fe0f897531d2ff6f7ef91d58"
    }
  },
  {
    "ts": null,
    "headline": "Why Investors Should Expect The July CPI To Tick Higher",
    "summary": "Tariff risks remain high for July CPI. A higher CPI print increases the likelihood of a Fed rate cut. Check out the expected implications of July CPI report.",
    "url": "https://finnhub.io/api/news?id=501f33d90b61d9605caccb84cfd16a2c41334b19f8bf3760b5797b84147ce991",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754399705,
      "headline": "Why Investors Should Expect The July CPI To Tick Higher",
      "id": 136214557,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2211730607/image_2211730607.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Tariff risks remain high for July CPI. A higher CPI print increases the likelihood of a Fed rate cut. Check out the expected implications of July CPI report.",
      "url": "https://finnhub.io/api/news?id=501f33d90b61d9605caccb84cfd16a2c41334b19f8bf3760b5797b84147ce991"
    }
  },
  {
    "ts": null,
    "headline": "Cabometyx Sales Miss Mark in Q2: What Does This Mean for EXEL Stock?",
    "summary": "EXEL rides on strong Cabometyx demand in RCC and NET, but Q2 sales miss and rising competition cloud the outlook.",
    "url": "https://finnhub.io/api/news?id=74aadfdf38f85f372d0b0324082794bf0413beb87e972767faadab80e17d84a9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754399400,
      "headline": "Cabometyx Sales Miss Mark in Q2: What Does This Mean for EXEL Stock?",
      "id": 136214444,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "EXEL rides on strong Cabometyx demand in RCC and NET, but Q2 sales miss and rising competition cloud the outlook.",
      "url": "https://finnhub.io/api/news?id=74aadfdf38f85f372d0b0324082794bf0413beb87e972767faadab80e17d84a9"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know",
    "summary": "Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
    "url": "https://finnhub.io/api/news?id=5887e91d13c0818c9402ee9f20336e15c7adcc3b222061faaba1909266840da6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754398803,
      "headline": "Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know",
      "id": 136215089,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=5887e91d13c0818c9402ee9f20336e15c7adcc3b222061faaba1909266840da6"
    }
  },
  {
    "ts": null,
    "headline": "Pharma prepared to work with Trump on DTC drug sales: Pfizer CEO",
    "summary": "Pfizer's Albert Bourla told investors that major drugmakers are \"ready to roll up their sleeves\" and build out more direct-to-consumer options.",
    "url": "https://finnhub.io/api/news?id=372a5d1dc8e76f732c71aea08aa2da1c7cd5516cc1f51d0d56216da3ccaad202",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754396220,
      "headline": "Pharma prepared to work with Trump on DTC drug sales: Pfizer CEO",
      "id": 136215090,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Pfizer's Albert Bourla told investors that major drugmakers are \"ready to roll up their sleeves\" and build out more direct-to-consumer options.",
      "url": "https://finnhub.io/api/news?id=372a5d1dc8e76f732c71aea08aa2da1c7cd5516cc1f51d0d56216da3ccaad202"
    }
  }
]